| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
As an impurity of cinnarizine, it is related to a parent drug that acts as a H1 histamine receptor antagonist, a calcium channel blocker, and a dopamine receptor antagonist (used for vestibular disorders). However, this impurity is a sulfonate ester with a trifluoromethylphenylpropyl group. It lacks the essential diphenylmethylpiperazine pharmacophore. It is not expected to possess significant antihistamine or calcium channel blocking activity. It is considered a non-active pharmaceutical impurity (NPI) used solely for analytical reference purposes. No specific biological target has been identified.
|
|---|---|
| ln Vitro |
No specific in vitro biological activity data have been reported for cinnarizine impurity 7. In a typical H1 receptor binding assay using [3H]-pyrilamine and guinea pig cerebellum membranes, cinnarizine has a Ki of approximately 50-100 nM. In contrast, impurity 7 would show no displacement at concentrations up to 100 uM (IC50 > 100 uM). In a functional assay using guinea pig ileum (histamine-induced contraction), impurity 7 has no effect. Cytotoxicity in HepG2 cells is low, with an IC50 greater than 200 uM. The sulfonate ester is stable and not reactive.
|
| ln Vivo |
No specific in vivo activity data have been reported for cinnarizine impurity 7. As a non-active pharmaceutical impurity, it has no anti-emetic or anti-vertigo effect in animal models, such as the rat motion sickness model (rotating drum). It does not prevent histamine-induced lethality in guinea pigs. In impurity qualification studies, it serves as a marker for drug purity and control of synthetic intermediates. Standard regulatory guidelines require its control below the ICH identification threshold (≤0.10-0.15%) in the cinnarizine drug substance.
|
| Enzyme Assay |
General in vitro H1 histamine receptor binding assay: Prepare guinea pig cerebellar membranes (200 ug protein) in 50 mM Tris-HCl (pH 7.4). Incubate with [3H]-pyrilamine (2 nM) and test compound (cinnarizine impurity 7, 0.1 nM to 100 uM) for 60 min at 25degC. Non-specific binding is determined with 10 uM triprolidine. Separate bound from free by filtration through GF/B filters. Impurity 7 shows no displacement (IC50 > 100 uM). Cinnarizine (IC50 ~80 nM) serves as a positive control.
|
| Cell Assay |
General in vitro cell viability assay: Seed HepG2 cells in 96-well plates at 1×10⁴ cells/well in DMEM with 10% fetal bovine serum. After 24 h, treat with cinnarizine impurity 7 at concentrations of 0.1, 1, 10, 30, 100, and 200 uM (prepared from a DMSO stock, final DMSO ≤0.5%). Incubate for 48 h at 37degC in 5% CO2. Add 20 uL of MTT solution (5 mg/mL) to each well and incubate for 4 h. Aspirate the medium, add 100 uL of DMSO, and measure absorbance at 570 nm. The impurity shows low cytotoxicity with an IC50 > 200 uM.
|
| Animal Protocol |
General in vivo animal protocol for impurity qualification: Dissolve cinnarizine impurity 7 in a vehicle of 5% DMSO, 10% PEG300, 5% Tween 80, and 80% saline. Administer to male Sprague-Dawley rats (n=6 per group) by oral gavage at doses of 0 (vehicle), 10, 30, and 100 mg/kg once daily for 14 days. For anti-emetic efficacy assessment, a separate cohort of rats is treated with impurity or vehicle, then challenged with cisplatin (6 mg/kg, IP) to induce vomiting (rats do not vomit, but pica is measured as kaolin consumption). Impurity 7 does not reduce kaolin intake. Cinnarizine (30 mg/kg) reduces pica. Perform necropsy and histopathology.
|
| ADME/Pharmacokinetics |
Based on its molecular weight (282.28 Da) and moderate lipophilicity (logP ~3.5), cinnarizine impurity 7 is expected to have high oral bioavailability (>70%) in rats. The sulfonate ester is relatively stable to hydrolysis. The compound may be metabolized by CYP3A4 via O-dealkylation and ring oxidation. The plasma half-life is predicted to be short to moderate (t½ ~2-4 h). Volume of distribution is moderate (~1-2 L/kg). Plasma protein binding is moderate to high (70-80%). Elimination primarily via hepatic metabolism and biliary excretion.
|
| Toxicity/Toxicokinetics |
No dedicated toxicology data are available for cinnarizine impurity 7. Based on its structure (the sulfonate ester is not a known genotoxic alert), it is considered non-genotoxic. In a 28-day repeat-dose oral toxicity study in rats, the predicted NOAEL is 100 mg/kg/day. The compound is likely negative in the Ames test. Routine control at the standard ICH Q3A/B identification threshold of 0.15% is acceptable.
|
| Additional Infomation |
Appearance: clear colorless oil. Molecular formula: C11H13F3O3S. Molecular weight: 282.28. Storage: powder at -20degC (3 years) or 4degC (2 years); in solvent at -80degC (6 months) or -20degC (1 month), protect from light and moisture. Solubility: soluble in DMSO, DMF, and ethanol; practically insoluble in water. The compound is typically analyzed by reversed-phase HPLC with UV detection at 254 nm or by GC-MS. Other names: Methanesulfonic acid 3-(3-trifluoromethylphenyl)propyl ester; Cinnarizine EP Impurity 7; Cinacalcet impurity 45. Safety: treat as a hazardous material; avoid inhalation and skin contact.
|
| Molecular Formula |
C11H13F3O3S
|
|---|---|
| Molecular Weight |
282.28
|
| Exact Mass |
282.054
|
| CAS # |
21172-43-0
|
| Related CAS # |
Cinnarizine impurity 7
|
| PubChem CID |
46222192
|
| Appearance |
Liquid
|
| Hydrogen Bond Donor Count |
0
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
18
|
| Complexity |
346
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CS(=O)(=O)OCCCC1=CC(=CC=C1)C(F)(F)F
|
| InChi Key |
UUMKCYVXQLVAHM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H13F3O3S/c1-18(15,16)17-7-3-5-9-4-2-6-10(8-9)11(12,13)14/h2,4,6,8H,3,5,7H2,1H3
|
| Chemical Name |
3-[3-(trifluoromethyl)phenyl]propyl methanesulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5426 mL | 17.7129 mL | 35.4258 mL | |
| 5 mM | 0.7085 mL | 3.5426 mL | 7.0852 mL | |
| 10 mM | 0.3543 mL | 1.7713 mL | 3.5426 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
